Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial

• Michael D. Hill ,

  * E-mail: michael.hill@ucalgary.ca

  Affiliation Departments of Clinical Neurosciences, Medicine, Radiology and Community Health Sciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

  ⨯
• Renee H. Martin,

  Affiliation Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Yuko Y. Palesch,

  Affiliation Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Claudia S. Moy,

  Affiliation Office of Clinical Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Diego Tamariz,

  Affiliation Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, United States of America

  ⨯
• Karla J. Ryckborst,

  Affiliation Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

  ⨯
• Elizabeth B. Jones,

  Affiliation Department of Emergency Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

  ⨯
• David Weisman,

  Affiliation Abington Neurological Associates, Abington, Pennsylvania, United States of America

  ⨯
• Creed Pettigrew,

  Affiliation Department of Neurology and Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentuck, United States of America

  ⨯
• Myron D. Ginsberg

  Affiliation Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, United States of America

  ⨯